Kratom manufacturers are modifying their products to avoid upcoming bans in Pennsylvania and New Jersey.

ATLANTIC CITY — As the annual CHAMPS trade show, the largest smoke shop expo in the United States, unfolded in Atlantic City, industry representatives rushed to sell off significant quantities of a controversial synthetic kratom product known as “7-OH.” This urgency stems from pending legislation in Pennsylvania and New Jersey aimed at banning these products, raising concerns about their future in the market.

7-Hydroxymitragynine, a potent laboratory-produced compound derived from the kratom plant, was prominently featured at the trade show, which attracted numerous vendors and buyers. Despite the impending legislative challenges, some exhibitors expressed confidence in their ability to adapt, indicating that their suppliers were already developing alternative products.

One such alternative is a new offering called “Cori,” introduced by Matt Swann, a former real estate investor turned 7-OH distributor based in Salt Lake City. This product, presented in a sleek green packaging, contains corydalis, a plant recognized for its pain-relieving properties similar to those of kratom but not targeted by current bans.

Swann emphasized that legislation poses the greatest threat to his business. He highlighted that the introduction of new formulations allows him to stay ahead of regulatory changes. Multiple sales representatives within the 7-OH sector reported modifications to their formulas proactively, seeking to evade restrictions motivated by growing concerns about the drug, often referred to as “gas station heroin” due to its high potential for abuse.

Federal authorities began measures last summer to classify 7-OH as a controlled substance amidst reports of misuse and increasing availability. A minimum of a dozen states have instituted or are considering bans on the compound, with active legislation in Pennsylvania and New Jersey.

In the burgeoning gray market for synthetic substances, including kratom, lab-made THC, and psychedelics, the delineation between legal and illegal can often depend on minute chemical variations. To navigate regulatory scrutiny, some companies have shifted from using 7-OH to alternative compounds, such as mitragynine pseudoindoxyl and 13-Hydroxy Mitragynine, which share similar effects.

While some proponents of kratom welcome the proposed restrictions on 7-OH and similar compounds, there are concerns that legislation could inadvertently impact natural, lower-potency kratom products. Swann advocates for the potential of such substances to serve as safer alternatives to opioids for managing chronic pain. He stressed the importance of informing consumers about the risk of dependency associated with kratom-derived products.

In recent legislative actions, Florida implemented an emergency ban specifically aimed at 7-OH, with states like Vermont prohibiting kratom and its associated alkaloids altogether. Likewise, New Jersey is advancing legislation to classify 7-OH as a controlled substance, with proposals that target related alkaloids and limit concentrations.

Despite the potential crackdown, there are concerns within the medical community about the impact of swift legislative action. Experts warn that banning 7-OH without adequate care resources may lead to sudden withdrawals for users. The trade show, characterized by its bustling atmosphere, reveals a complex interplay between market demands, legislative pressures, and public health considerations in the evolving landscape of synthetic drugs.

As more manufacturers explore loopholes to keep their products on the shelves, the dialogue around kratom, 7-OH, and its alternatives illustrates an ongoing challenge in balancing consumer safety with market viability. Proponents of kratom emphasize the need for legislative clarity to differentiate between traditional, low-potency products and concentrated synthetics, aiming for a regulated market that prioritizes user safety while preserving access to beneficial natural remedies.

As discussions continue, industry stakeholders await the implications of forthcoming legislation on the future of kratom and its derivatives in an increasingly controlled environment.